Exploring the Significance of the Exon 4-Skipping Isoform of the ZNF217 Oncogene in Breast Cancer
The DOI matches its Crossref record.
Abstract
Oncogene alternative splicing events can create distinct functional transcripts that offer new candidate prognostic biomarkers for breast cancer. ZNF217 is a well-established oncogene but its exon 4-skipping isoform (ZNF217-ΔE4) has never been investigated in terms of clinical or biological relevance. Using in silico RNA-seq and RT-qPCR analyses, we demonstrated for the first time the existence of ZNF217-ΔE4 transcripts in primary breast tumors, and a positive correlation between ZNF217-ΔE4 mRNA levels and those of the wild-type oncogene (ZNF217-WT). A pilot retrospective analysis revealed that, in the Luminal subclass, the combination of the two ZNF217 variants (the ZNF217-ΔE4-WT gene-expression signature) provided more information than the mRNA expression levels of each isoform alone. Ectopic overexpression of ZNF217-ΔE4 in breast cancer cells promoted an aggressive phenotype and an increase in ZNF217-WT expression levels that was inversely correlated with DNA methylation of the ZNF217 gene. This study provides new insights into the possible role of the ZNF217-ΔE4 splice variant in breast cancer and suggests a close interplay between the ZNF217-WT and ZNF217-ΔE4 isoforms. Our data suggest that a dual signature combining the expression levels of these two isoforms may serve as a novel prognostic biomarker allowing better stratification of breast cancers with good prognosis and aiding clinicians in therapeutic decisions.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“ZNF217 encodes distinct protein isoforms due to the presence or absence of exon 4.24”
From Regulation of RNA splicing in endometrial tissue and its association with endometriosis (2025) · cites this paper as [24]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
No references could be resolved yet.
Research works printed but not linked: 29
- Collins, 1998, Positional Cloning of ZNF217 and NABC1: Genes Amplified at 20q13.2 and Overexpressed in Breast Carcinoma, Proc Natl Acad Sci USA, 95, 10.1073/pnas.95.15.8703 · DOI · Paper page
- Cohen, 2015, The Dark Side of ZNF217, A Key Regulator of Tumorigenesis With Powerful Biomarker Value, Oncotarget, 6, 10.18632/oncotarget.5893 · DOI
- Thollet, 2010, ZNF217 Confers Resistance to the Pro-Apoptotic Signals of Paclitaxel and Aberrant Expression of Aurora-a in Breast Cancer Cells, Mol Cancer, 9, 10.1186/1476-4598-9-291 · DOI
- Vendrell, 2012, ZNF217 Is a Marker of Poor Prognosis in Breast Cancer That Drives Epithelial-Mesenchymal Transition and Invasion, Cancer Res, 72, 10.1158/0008-5472.CAN-11-3095 · DOI
- Bellanger, 2017, The Critical Role of the ZNF217 Oncogene in Promoting Breast Cancer Metastasis to the Bone, J Pathol, 242, 73, 10.1002/path.4882 · DOI
- Nguyen, 2014, A Functional Interplay Between ZNF217 and Estrogen Receptor Alpha Exists in Luminal Breast Cancers, Mol Oncol, 8, 10.1016/j.molonc.2014.05.013 · DOI · Paper page
- Ladomery, 2013, Aberrant Alternative Splicing is Another Hallmark of Cancer, Int J Cell Biol, 2013, 10.1155/2013/463786 · DOI · Paper page
- Martinez-Montiel, 2017, Alternative Splicing in Breast Cancer and the Potential Development of Therapeutic Tools, Genes (Basel), 8, 10.3390/genes8100217 · DOI
- Koboldt, 2012, Comprehensive Molecular Portraits of Human Breast Tumours, Nature, 490, 61, 10.1038/nature11412 · DOI · Paper page
- Stephenson, 1971, Induction of Colonies of Hemoglobin-Synthesizing Cells by Erythropoietin In Vitro, Proc Natl Acad Sci USA, 68, 10.1073/pnas.68.7.1542 · DOI · Paper page
- Gnant, 2011, St. Gallen 2011: Summary of the Consensus Discussion, Breast Care (Basel), 6, 10.1159/000328054 · DOI · Paper page
- Goldhirsch, 2011, Strategies for Subtypes–Dealing With the Diversity of Breast Cancer: Highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011, Ann Oncol, 22, 10.1093/annonc/mdr304 · DOI · Paper page
- Goldhirsch, 2013, Personalizing the Treatment of Women With Early Breast Cancer: Highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013, Ann Oncol, 24, 10.1093/annonc/mdt303 · DOI · Paper page
- Etcheverry, 2010, DNA Methylation in Glioblastoma: Impact on Gene Expression and Clinical Outcome, BMC Genomics, 11, 10.1186/1471-2164-11-701 · DOI · Paper page
- Leu, 2004, Loss of Estrogen Receptor Signaling Triggers Epigenetic Silencing of Downstream Targets in Breast Cancer, Cancer Res, 64, 10.1158/0008-5472.CAN-04-2045 · DOI · Paper page
- Ness, 2021, Integrated Differential DNA Methylation and Gene Expression of Formalin-Fixed Paraffin-Embedded Uveal Melanoma Specimens Identifies Genes Associated With Early Metastasis and Poor Prognosis, Exp Eye Res, 203, 10.1016/j.exer.2020.108426 · DOI
- Renner, 2013, Integrative DNA Methylation and Gene Expression Analysis in High-Grade Soft Tissue Sarcomas, Genome Biol, 14, 10.1186/gb-2013-14-12-r137 · DOI
- Trincado, 2016, The Prognostic Potential of Alternative Transcript Isoforms Across Human Tumors, Genome Med, 8, 85, 10.1186/s13073-016-0339-3 · DOI
- Yang, 2019, Aberrant Alternative Splicing in Breast Cancer, J Mol Cell Biol, 11, 10.1093/jmcb/mjz033 · DOI
- Venables, 2008, Identification of Alternative Splicing Markers for Breast Cancer, Cancer Res, 68, 10.1158/0008-5472.CAN-08-1769 · DOI · Paper page
- Yang, 2020, Novel Alternative Splicing Variants of Klf4 Display Different Capacities for Self-Renewal and Pluripotency in Mouse Embryonic Stem Cells, Biochem Biophys Res Commun, 532, 10.1016/j.bbrc.2020.08.054 · DOI
- Syafruddin, 2020, Two Sides of the Same Coin: The Roles of KLF6 in Physiology and Pathophysiology, Biomolecules, 10, 1378, 10.3390/biom10101378 · DOI
- Wang, 2018, Context-Dependent Functions of KLF4 in Cancers: Could Alternative Splicing Isoforms Be the Key, Cancer Lett, 438, 10.1016/j.canlet.2018.09.005 · DOI
- Zhang, 2019, The KLF6 Splice Variant KLF6-SV1 Promotes Proliferation and Invasion of Non-Small Cell Lung Cancer by Up-Regultating PI3K-AKT Signaling Pathway, J Cancer, 10, 10.7150/jca.34212 · DOI
- Widschwendter, 2008, Epigenotyping in Peripheral Blood Cell DNA and Breast Cancer Risk: A Proof of Principle Study, PloS One, 3, e2656, 10.1371/journal.pone.0002656 · DOI
- Cowger, 2007, Biochemical Characterization of the Zinc-Finger Protein 217 Transcriptional Repressor Complex: Identification of a ZNF217 Consensus Recognition Sequence, Oncogene, 26, 10.1038/sj.onc.1210126 · DOI
- Quinlan, 2006, Specific Recognition of ZNF217 and Other Zinc Finger Proteins At a Surface Groove of C-Terminal Binding Proteins, Mol Cell Biol, 26, 10.1128/MCB.00680-06 · DOI · Paper page
- Adhikari, 2016, M5A: Signaling for mRNA Splicing, RNA Biol, 13, 10.1080/15476286.2016.1201628 · DOI
- Aguilo, 2015, Coordination of m6A mRNA Methylation and Gene Transcription by ZFP217 Regulates Pluripotency and Reprogramming, Cell Stem Cell, 17, 689, 10.1016/j.stem.2015.09.005 · DOI · Paper page
Cited by
Regulation of RNA splicing in endometrial tissue and its association with endometriosis
Yang, F., Qi, T., McRae, A. F., Rogers, P. A. W., Montgomery, G. W., & Mortlock, S. (2025) · iScience · doi:10.1016/j.isci.2025.113207 · Cited by 4
Metadata
- Authors
- Bellanger, A., Le, D. T., Vendrell, J., Wierinckx, A., Pongor, L. S., Solassol, J., Lachuer, J., Clezardin, P., Győrffy, B., & Cohen, P. A.
- Venue
- Frontiers in Oncology
- Publisher
- Frontiers Media SA
- Published
- 2021-07-02
- Volume
- 11
- ISSN
- 2234-943X
- Cited by
- 7
- References
- 0
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Exploring the Significance of the Exon 4-Skipping Isoform of the ZNF217 Oncogene in Breast Cancer. https://app.cochat.ai/papers/10.3389/fonc.2021.647269
- The paper
- Bellanger, A., Le, D. T., Vendrell, J., Wierinckx, A., Pongor, L. S., Solassol, J., Lachuer, J., Clezardin, P., Győrffy, B., & Cohen, P. A. (2021). Exploring the Significance of the Exon 4-Skipping Isoform of the ZNF217 Oncogene in Breast Cancer. Frontiers in Oncology. https://doi.org/10.3389/fonc.2021.647269
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.